A bipartisan coalition of U.S. senators has introduced significant legislation aimed at advancing research into the therapeutic applications of psychedelic compounds.

The proposed bill seeks to establish a dedicated office within the Department of Veterans Affairs (VA), specifically tasked with promoting and facilitating the development of innovative treatments for serious mental health conditions prevalent among veterans. A key component of this new VA office would be its role in assisting with the review of the scheduling status for various psychedelic drugs, including psilocybin and ibogaine. This legislative initiative underscores a growing federal interest in exploring alternative mental health interventions and could signal a shift in the regulatory landscape concerning substances currently classified under strict federal schedules.